scholarly journals 5PSQ-072 Acute promyelocytic leukaemia after infliximab therapy in a crohn’s disease patient: a case report and a review of the literature

Author(s):  
L Camuffo ◽  
MV Lucatelli ◽  
G Pieri ◽  
C Bacci ◽  
G Inzalaco ◽  
...  
2020 ◽  
Vol 6 (1) ◽  
pp. 14-21
Author(s):  
Andreas Sakkas ◽  

Abstract: Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication, occurring to patients undergoing treatment with antiresorptive medication, such as bisphosphonates, denosumab or bevacizumab, for different oncologic and non-oncologic diseases. The aim of this study is to report a case of MRONJ in a young patient treated with infliximab, a tumor necrosis factor-a inhibitor used in the treatment of immune-mediated inflammatory diseases such Crohn’s disease, ulcerative colitis, ankylosing spondylitis, rheumatoid and psoriatic arthritis. Case Report: A 27-year-old female patient diagnosed with Crohn’s disease, who had been undergoing intravenous infliximab therapy every seven weeks for 8 years, sought our oral and plastic maxillofacial department with a peri-mandibular abscess for further treatment. The patient underwent surgical treatment, including the extraoral sub-mandibular incision of the abscess and the extraction of the lower second premolar under the administration of intravenous antibiotics. We traced a wound dehiscence and delayed healing procedure of the extraction’s alveolar bone, and five weeks later, the patient returned with an abscess recurrence around the mandibular angle area. The patient underwent surgical treatment with wide bone resection and debridement of the necrotic tissues. After follow-up (4 months), the patient completely healed without signs of recurrence. Discussion: Osteomyelitis of the jaw by patients treated with infliximab has been sparsely described in publications. This case confirms the potential role of infliximab in the pathogenesis of MRONJ. Since the pathomechanism of MRONJ under infliximab therapy remains unclear, we recommend a regular oral check-up before starting therapy, as well as during the therapy with infliximab, in order to possibly prevent the MRONJ onset. Keywords: Medication-Related Osteonecrosis of the Jaw, Infliximab, TNF-a Inhibitors, Crohn’s Disease and Osteomyelitis.


2009 ◽  
Vol 2 ◽  
pp. CCRep.S2204 ◽  
Author(s):  
Cherag Daruwala ◽  
Giancarlo Mercogliano ◽  
Gary Newman ◽  
Mark J. Ingerman

Objective The purpose of this study is to report a case of C. difficile bacteremia in a Crohn's disease patient and to review the literature on previously reported cases. Methods Searches of MEDLINE and PubMed databases were made. Results We report the first case of C. difficile bacteremia in a Crohn's disease patient. There are 15 other reported cases of C. difficile bacteremia reported in the literature. We found that the majority of patients (10 of 15 patients) had polymicrobial bacteremia and that the overall mortality rate is significant, with 6 of 15 reported patients dying. Conclusion In conclusion, we find that C. difficile bacteremia is associated with a significant mortality rate and it would seem prudent to consider aggressive antibiotic therapy.


2014 ◽  
Vol 2014 (may19 1) ◽  
pp. bcr2013203318-bcr2013203318 ◽  
Author(s):  
F. Mohammad ◽  
A. Vivekanandarajah ◽  
H. Haddad ◽  
C. M. Shutty ◽  
M. T. Hurford ◽  
...  

2005 ◽  
Vol 43 (05) ◽  
Author(s):  
R Schwab ◽  
P Lakatos ◽  
E Schäfer ◽  
J Weltner ◽  
A Sáfrány ◽  
...  

2009 ◽  
Vol 3 (4) ◽  
pp. 302-304 ◽  
Author(s):  
Syed F. Habib ◽  
Muhammad Z. Hasan ◽  
I. Salam

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Hamza Mohammed ◽  
Rana Bokhary ◽  
Mohammed Nassif ◽  
Mahmoud Mosli

We present to you a rare case of Crohn’s disease involving the ovary in a 28-year-old nulligravida Eritrean patient. This is considered a rare manifestation of Crohn’s disease that is believed to be due to fistulization between the ovary and intestines.


2020 ◽  
Vol Volume 12 ◽  
pp. 133-137
Author(s):  
Satohiro Matsumoto ◽  
Keita Matsumoto ◽  
Hiromu Takaya ◽  
Haruka Otake ◽  
Hirosato Mashima

Sign in / Sign up

Export Citation Format

Share Document